SCHEMBL7213155

SCHEMBL7213155

NC(=O)c1cn([C@H]2O[C@H](CO)[C@@H](O)[C@H]2O)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 3/20 0.57
TSHR P16473 2/20 0.57
THPO P40225 2/20 0.57
PMP22 Q01453 2/20 0.57
ADORA1 P30542 2/20 0.57
GLA P06280 1/20 0.57
EIF4E P06730 1/20 0.57
CYP3A4 P08684 1/20 0.57
TOP1 P11387 1/20 0.57
KDM4E B2RXH2 2/20 0.56
HTT P42858 2/20 0.56
BLM P54132 2/20 0.56
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
GAA P10253 1/20 0.56
PNP P00491 2/20 0.48
GMNN O75496 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6385747 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL2481555 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12676402 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12669988 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL8722885 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL15916868 0.87 LMNA (0.49) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL28863454 0.84 TP53 (0.48) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL17993314 0.83 LMNA (0.46) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL24024486 0.82 ATIC (0.62) SMN1; SMN2ADORA1
SCHEMBL29687021 0.82 ATIC (0.62) SMN1; SMN2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA SAMHD1, BCDIN3D, DCTD LMNA 3576/4885SMN1; SMN2 2456/4885ALDH1A1 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.